As breast cancer comprises four major subtypes with specific molecular drivers and histological characteristics (Cancer Genome Atlas Network 2012), new clinical trials should be tailored only to select groups of patients whose tumor genetics and PR target gene signatures make them suitable candidates to likely benefit from antiprogesterone therapy. This evidence concerns the gene PGR and neoplasm.